series-a
Stage
1
Investors
About
Angiex develops Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) to deliver chemotherapeutic agents directly to the nuclei of tumor and tumor blood vessel cells for the treatment of solid tumors.
Explore Angiex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.